Avicenna HP-7.5 Class IV Therapeutic Laser Research
Our objective is to conduct and report research pertaining to the efficacy, cost effectiveness and safety of the Avicenna Class IV Therapeutic Laser with eventual dissemination of peer reviewed papers (original research, literature reviews, editorials, case reports or series, discussions) within appropriate well respected industry specific journals.
Our aim is to stay at the forefront of issues in the therapeutic laser community. We strongly believe in reporting the results of studies dealing with the latest advances in laser therapy. These elements include, but are not limited to, clinical outcomes, cost-effectiveness, treatment protocols, product parameters, and relative performance under various types of patient populations. Currently, research is underway at two major medical institutions investigating HPLT for post-operative pain management and wound healing in thoracic and spinal surgery patients.
We have performed an analysis of a number of frequently cited studies utilized to refute the efficacy of laser therapy. In many of these studies, our analysis uncovered several reasons for negative outcomes. The most common cause of poor clinical outcomes related to the use of extremely low therapeutic laser doses. Other reasons were: faulty inclusion criteria, inaccurate control group definition, ineffective methods of therapy, small patient populations, and low power density. Another weakness frequently encountered in these studies was failure to provide sufficient data on laser parameters. Since negatively inclined studies are often quoted as "proof" of the ineffectiveness of laser therapy, it is important that research utilizing the Avicenna Class IV Therapeutic Laser address the aforementioned issues.
Laser therapy is a relatively young science. Early medical laser researchers had, and in many cases still have, a rather diffuse knowledge of laser physics. Qualified books on the physics of laser therapy continue to be limited in number. In many cases, the only information available to researchers on doses, methods of treatment and suitable indications came from manufacturers or sales representative, while overly optimistic, often laid traps ensnaring both themselves and researchers. Avicenna has assembled a team of professionals who individually represent the best-in-class for their particular field. We look forward to working with any institution who shares our desire to further investigate this emerging technology and its potential to enhance the quality of life for those individuals with musculoskeletal-related conditions.